SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)

被引：0

作者：

Dimopoulos, M. ^{[1
]}

Trotman, J. ^{[2
]}

Tedeschi, A. ^{[3
]}

Matous, J. V. ^{[4
]}

Macdonald, D. ^{[5
]}

Tam, C. ^{[6
,7
]}

Tournilhac, O. ^{[8
]}

Ma, S. ^{[9
]}

Oriol, A. ^{[10
]}

Heffner, L. ^{[11
]}

Shustik, C. ^{[12
]}

Garcia-Sanz, R. ^{[13
]}

Cornell, R. F. ^{[14
]}

Fernandez de Larrea, C. ^{[15
]}

Castillo, J. J. ^{[16
]}

Granell, M. ^{[17
]}

Kyrtsonis, M. C. ^{[18
]}

Leblond, V. ^{[17
,19
]}

Symeonidis, A. ^{[20
]}

Singh, P. ^{[21
]}

Li, J. ^{[21
]}

Graef, T. ^{[21
]}

Bilotti, E. ^{[21
]}

Treon, S. ^{[16
]}

Buske, C. ^{[22
]}

机构：

[1] Univ Athens, Sch Med, Athens 11528, Greece

[2] Univ Sydney, Concord Hosp, Sydney, NSW 2006, Australia

[3] Osped Niguarda Ca Granda, Milan, Italy

[4] Colorado Blood Canc Inst, Denver, CO USA

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Peter MacCallum Canc Ctr, Melbourne, Australia

[7] St Vincents Hosp, Melbourne, Australia

[8] CHU Clermont Ferrand, Hematol Clin Adulte & Therapie Cellulaire, Clermont Ferrand, France

[9] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[10] Hosp Badalona Germans Trias & Pujol, Catala Oncol 9Inst, Barcelona, Spain

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] McGill Univ Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada

[13] Hosp Univ Salamanca, Salamanca, Spain

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Hosp Sant Pau, Barcelona, Spain

[18] Univ Athens, Athens 11528, Greece

[19] UPMC Univ Paris, Hop Pitie Salpetriere APHP, Paris, France

[20] Univ Patras, Medial Sch, Patras, Greece

[21] AbbVie Co, Pharmacyclics LLC, Sunnyvale, CA USA

[22] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, INNOVATE TM Study Grp, Ulm, Germany

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P652

引用

页码：256 / 257

页数：2

共 50 条

[21] Bendamustine in patients with rituximab-refractory indolent and transformed non-hodgkin's lymphoma: Results from a phase II multicenter, single-agent study (vol 26, pg 204, 2008)
Friedberg
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1911 - 1911
[22] Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China
Gao, Yan
Liu, Yizhen
Wang, Yafei
Zhang, Qingyuan
Wu, Depei
Ye, Xu
Wu, Jianqiu
Xu, Wei
Zhou, Jianfeng
Yang, Yu
Cen, Hong
Zhang, Feng
Xiang, Ying
Tang, Xiaoqiong
Ding, Kaiyang
Lin, JinYing
Ma, Lei
Wang, Shunqing
Yu, Hao
Zhao, Yang
Song, Bin
Lv, Fangfang
Huang, Huiqiang
CANCER, 2023, 129 (04) : 551 - 559
[23] Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study
Vij, Ravi
Savona, Michael
Siegel, David S.
Kaufman, Jonathan L.
Badros, Ashraf
Ghobrial, Irene M.
Paner, Agne
Jagannath, Sundar
Jakubowiak, Andrzej
Mikhael, Joseph R.
Kapoor, Prashant
Neuman, Linda L.
Lee, Ju RueyJiuan
Berdeja, Jesus G.
BLOOD, 2014, 124 (21)
[24] Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia
Thomas, Sheeba K.
Harb, Wael A.
Beck, Joseph Thaddeus
Nashat, Gabrail
Palomba, M. Lia
Ansell, Stephen M.
Eradat, Herbert
Libby, Edward N., III
Advani, Ranjana H.
Hajdenberg, Julio
Heffner, Leonard T.
Hoffman, James
Vesole, David H.
Simov, Lindsey
Wyant, Nancy
Brevard, Julie
O'Leary, James
Agrawal, Sudhir
BLOOD, 2015, 126 (23)
[25] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
Richardson, P
Jagannath, S
Hussein, M
Berenson, J
Singhal, S
Irwin, D
Williams, SF
Bensinger, W
Badros, AZ
Vescio, R
Kenvin, L
Yu, ZN
Olesnyckyj, M
Faleck, H
Zeldis, J
Knight, R
Anderson, KC
BLOOD, 2005, 106 (11) : 449A - 449A
[26] Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Siegel, David S.
Oriol, Albert
Rajnics, Peter
Minarik, Jiri
Hungria, Vania
Lee, Jae Hoon
Song, Kevin
Obreja, Mihaela
Aggarwal, Sanjay
Hajek, Roman
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E142 - E142
[27] Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies
Ghobrial, Irene M.
Savona, Michael R.
Vij, Ravi
Siegel, David S.
Badros, Ashraf
Kaufman, Jonathan L.
Raje, Noopur
Jakubowiak, Andrzej
Obreja, Mihaela
Berdeja, Jesus G.
BLOOD, 2016, 128 (22)
[28] Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)
Wang, Luhua
Siege, David
Kaufman, Jonathan L.
Stewart, A. Keith
Jakubowiak, Andrzej J.
Alsina, Melissa
Kukreti, Vishal
Bahlis, Nizar J.
McDonagh, Kevin T.
Belch, Andrew
Sebag, Michael
Gabrail, Nashat
Le, Mai H.
Bennett, Mark K.
Kunkel, Lori
Kauffman, Michael
Orlowski, Robert Z.
Vij, Ravi
BLOOD, 2009, 114 (22) : 127 - 128
[29] PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
Siegel, David
Wang, Luhua
Orlowski, Robert Z.
Kaufman, Jonathan L.
Stewart, A. Keith
Kukreti, Vishal
Alsina, Melissa
Jakubowiak, Andrzej J.
Jagannath, Sundar
McDonagh, Kevin T.
Belch, Andrew
Bahlis, Nizar J.
Shustik, Chaim
Le, Mai H.
Kunkel, Lori
Bennett, Mark K.
Kauffman, Michael
Vij, Ravi
BLOOD, 2009, 114 (22) : 128 - 128
[30] A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation
Shapira-Frommer, R.
Oza, A.
Domchek, S. M.
Balmana, J.
Patel, M. R.
Chen, L. M.
Drew, Y.
Burris, H. A., III
Korach, J.
Flynn, M.
Bowering, V. L.
Morgan, M. A.
Watkins, S. P.
Simpson, D.
Goble, S.
Maloney, L.
Kristeleit, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S545 - S545

← 1 2 3 4 5 →